Vaccine Marketing - Innovation and Marketing in the Pharmaceutical Industry - page 365

Table 13.3 Competitor shares by selected regions and countries
Western
Europe (%)

Latin
America (%) China (%) India (%) Russia (%)

Sanofi Pasteur 29 10 36 20

Sanofi Pasteur MSD 36

GlaxoSmithKline 30 23 10 12 8

Merck & Co. 6 Other multinational

companies: 3

NA 2

Pfi zer 16 27 NA NA

Novartis 7 2 10 2

Subtotal 89 87 23 58 32

Others 11 13 77 42 68

Source : Sanofi Aventis, Vaccines IR Seminar, December 17th, 2009

Fig. 13.2 Competitor share in selected franchises, North America. Source : Sanofi Aventis,
Vaccines IR Seminar, December 17th, 2009

position in countries where their presence is still low, the big fi ve have engaged in a
multitude of deals and alliances with local manufacturers (Kresse and Shah 2010 ).
Concentration is very high in many franchises and indications. For example,
Pasteur had a 100 % share of the Meningitis vaccine market in North America in
2009 (see Fig. 13.2 ). In the United States, 57 % of the 30 vaccine/age classes with
Advisory Committee on Immunization Practices (ACIP)-recommended vaccines